Vijaypavan

For companies who are developing a drug with some of the characteristics we are testing our survey results reveal the standards that surveyed physicians expect the remainder of the drugs clinical profile to meet. Our analysis begins to uncover physician-expected drug attributes as well as acceptable trade-offs in emerging therapies. Our primary research with practicing physicians includes this emerging therapys anticipated patient share projected use by line of therapy and forecasted sales. \r\nFor companies that already have a drug launched for the indication in question our data and analysis show the impact an emerging drug would have on their brands market. Not only does our research reveal which existing brands would be replaced by a drug meeting the Target Product Profile but it also clearly outlines whether any drugs in the pipeline will meet the criteria laid out by physicians to challenge the existing sales leader. This knowledge gives existing brands the information they need to protect their share either through new clinical trials aimed at end points physicians say are critical differentiators or by aggressive marketing of brand attributes that emerging agents will not be able to beat. \r\nFor companies looking to enter a disease through licensing or acquisition the challenge of sifting through tens or hundreds of early-stage candidates can be daunting. Our Target Product Profiles can quickly show business development teams the clinical attributes that are unique versus products already on the market and our primary research with physicians quickly identifies likely share and market potential to give a first glimpse at valuation. Because all of our Target Product Profiles are designed to be attainable within the next decade our research can be a fast and efficient way to whittle the field.